Arcturus Therapeutics is trading at $11.98, up 7.73%, with no clear catalyst identified for the October 15 pre-market gain. - No new company-specific explanation was found; the latest located announcement, dated September 23, reported interim Phase 2 results and a new mRNA platform. - Broader markets were mixed to weaker, with Nasdaq futures down 1.29%; available evidence does not establish a market-wide explanation. - Recent CPI-related selling described pressure on shares, not today’s rebound; pre-market volume information was unavailable.